Brief: Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results From Phase 2 Apex Trial Of Zumilokibart In Moderate-To-Severe Atopic Dermatitis
27/05/2026 14:24
BRIEF-Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results From Phase 2 Apex Trial Of Zumilokibart In Moderate-To-Severe Atopic Dermatitis May 27 (Reuters) - Apogee Therapeutics Inc APGE.O:
APOGEE THERAPEUTICS ANNOUNCES POSITIVE 16-WEEK PART B INDUCTION DOSE OPTIMIZATION RESULTS FROM PHASE 2 APEX TRIAL OF ZUMILOKIBART IN MODERATE-TO-SEVERE ATOPIC DERMATITIS
APOGEE THERAPEUTICS INC - TO ADVANCE MID-DOSE ZUMILOKIBART TO PHASE 3 TRIALS IN AD IN 2H 2026
APOGEE THERAPEUTICS INC - ZUMILOKIBART SHOWS FAVORABLE SAFETY PROFILE CONSISTENT WITH CLASS
APOGEE THERAPEUTICS INC - ANNOUNCES STRATEGIC FINANCING COLLABORATION WITH BLACKSTONE LIFE SCIENCES
APOGEE THERAPEUTICS INC - PHASE 2 APEX CLINICAL TRIAL MET ITS PRIMARY AND SECONDARY ENDPOINTS
Source text: ID:nGNX1x2xJC
Further company coverage: APGE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apogee Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Abbvie Seeks At Least $8 Billion In Debt To Fund Apogee Deal - Bloomberg News
Street View: Strength in AbbVie's immunology pipeline to support revenue growth
AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates (updated)